Company intelligence / Profile preview

Mthera Pharma

Ownership: Private
Development stage: Phase 1

Overview

Mthera Pharma develops first-in-class botanical and multi-modal therapeutics targeting chronic and difficult-to-treat diseases using a proprietary multi-target approach. Lead assets are in Phase 2 clinical trials for cachexia and Parkinson’s disease. The company leverages advanced CMC technology to meet FDA standards and utilizes AI-based bio-fingerprinting alongside omics technologies to drive its R&D pipeline. Recent partnerships include licensing deals with NeuroBo Pharmaceuticals and an MoU with Yuhan Corporation.

Therapeutic areas: OtherGastroenterologyNeurologyInfectious Diseases
Modalities: Herbal medicineCell therapyCAR-TSmall molecule drugOligonucleotide
Industry: Biotech

Drug pipeline

10 assets

MSP01-T

9 more assets in the full pipeline.

Request access →

Partnerships

NeuroBo Pharmaceuticals – exclusive license agreement for NB‑01Yuhan Corporation – Memorandum of Understanding signed April 2024.

Beyond the preview

Go deeper on Mthera Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mthera Pharma.

Explore the full profile